Abcam, ab254018, T Cell Exhaustion Marker (PD1, CTLA4, TIM3, LAG3, TIGIT) Antibody Panel - Human, IHC

Size: 1Kit
T Cell Exhaustion Marker (PD1, CTLA4, TIM3, LAG3, TIGIT) Antibody Panel - Human, IHC (ab254018) is part of the multiplex kits range. Abcam offers high-quality biological reagents and tools including antibodies, proteins, assays, cell lines and lysates.
Key facts
Reacts with:Human,
Target:PDCD1See target data

Product details:
T Cell Exhaustion Marker (PD1, CTLA4, TIM3, LAG3, TIGIT) Antibody Panel - Human, IHC ab254018 contains multiple trial-sized versions of anti-human antibody clones against PD1, CTLA4, TIM3, LAG3, TIGIT, specifically selected for high performance in IHC. This panel contains 4 recombinant rabbit monoclonal antibodies against human CTLA4, TIM3, LAG3, TIGIT and 1 mouse monoclonal antibody against human PD1. They are provided as a sampler panel to allow you to easily evaluate each in your required applications.
For guidelines on how to use each antibody within the panel, please consult the individual datasheet for each antibody.
Panel contains:
- Mouse monoclonal [NAT105] to PD1 (20 μg)
ab52587
- Rabbit monoclonal [CAL49] to CTLA4 (20 μL)
ab237712
- Rabbit monoclonal [EPR22241] to TIM 3 (20 μL)
ab241332
- Rabbit monoclonal [EPR20261] to LAG-3 (20 μL)
ab209236
- Rabbit monoclonal [BLR047F] to TIGIT (20 μL)
ab243903
Explore our range of antibody sample panels designed to provide you with a variety of trial-size antibodies in a convenient and cost-effective format.
Carrier-free formulations of our recombinant antibodies are also available for easy conjugation to labels of your choice and for multiplex applications. Use our intuitive search and select carrier-free or your label of choice. For bespoke conjugations or large volumes email bespoke@abcam.com.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CTLA4 TIM-3 PD1 LAG-3 and TIGIT are important immune checkpoint proteins that play integral roles in regulating immune responses. Commonly referred to by their official gene symbols these proteins act as negative regulators of immune activation. CTLA4 for instance is a protein with an approximate molecular mass of 25 kDa and is expressed mainly on activated T cells and regulatory T cells. PD1 or Programmed cell death protein 1 shares a similar function and is expressed on T cells B cells and myeloid cells. LAG-3 (Lymphocyte-activation gene 3) and TIGIT (T cell immunoreceptor with Ig and ITIM domains) also contribute to immune modulation by limiting T cell activation. These proteins serve as exhaustion markers on T cells indicating immune regulation.
Biological function summary
These checkpoint proteins are part of the immune system's regulatory machinery and function to maintain self-tolerance and control immune responses to prevent tissue damage. For example CTLA4 competes with CD28 for binding to B7 molecules modulating early T cell activation. PD1 and its ligands PD-L1 and PD-L2 deliver inhibitory signals that reduce T cell activity. TIM-3 interacts with various ligands and has roles in T cell exhaustion. LAG-3 and TIGIT also convey inhibitory signals that reduce the activity of T cells through distinct mechanisms making them key exhaustion markers in the immune system.
Pathways
These immune checkpoints are closely linked to the immune synapse and adaptive immune pathways. CTLA4 and PD1 play central roles in the PD-1/PD-L1 and CTLA-4 pathways which are critical for immune homeostasis and tolerance. CTLA4 interacts with CD80 and CD86 part of the CD28 family pathway to modulate T cell responses. PD1 associates with its ligand PD-L1 in pathways that control the fine balance of immunity. LAG-3 and TIM-3 also participate in signaling pathways that regulate T cell exhaustion tying their function to critical immune regulation networks.
These immune checkpoint proteins have significant implications in cancer and autoimmune diseases. Dysregulation and overexpression of CTLA4 and PD1 are associated with cancer's ability to evade the immune system marking their importance as exhaustion markers in tumor environments. LAG-3 and TIGIT are also involved with LAG-3 contributing to cancer and autoimmune conditions by interfering with normal immune activity. Autoimmune disorders see alterations in these pathways where inadequate checkpoint function leads to excessive immune activity. Understanding their role is pivotal in developing therapies that target these checkpoint proteins for anti-cancer and autoimmunity treatments.